Screener
Phathom Pharmaceuticals, Inc. PHAT Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Phathom Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCash.
The source filing: Phathom Pharmaceuticals, Inc.’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 7:05 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-324867
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Total current assets | 295,915 | 228,972 |
| Property and equipment, net | 971 | 1,064 |
| Operating lease right-of-use assets | 2,410 | 2,603 |
| Restricted cash | 2,864 | 2,861 |
| Inventory, non-current | 21,827 | 20,732 |
| Other long-term assets | 3,088 | 2,917 |
| Total assets | $327,075 | $259,149 |
| Liabilities and Stockholders’ Deficit |
Item 1. Financial Statements (unaudited)
FAQ
- What is Phathom Pharmaceuticals, Inc.'s restricted cash?
- Phathom Pharmaceuticals, Inc. (PHAT) reported restricted cash of $2.86M in Q2 2026.
- How has Phathom Pharmaceuticals, Inc.'s restricted cash changed year-over-year?
- Phathom Pharmaceuticals, Inc.'s restricted cash increased by 0.1% year-over-year, from $2.86M to $2.86M.
- What is the long-term trend for Phathom Pharmaceuticals, Inc.'s restricted cash?
- Over 4 years (2021 to 2025), Phathom Pharmaceuticals, Inc.'s restricted cash has grown at a 105.6% compound annual growth rate (CAGR), from $160K to $2.86M.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about Phathom Pharmaceuticals, Inc.'s restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude